Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children

HUANG Liang; WANG Qiqiong; CHEN Li; YU Dan; WU Jin; LIN Yunzhu; ZENG Linan; JIA Zhijun; CHENG Guo; ZHANG Lingli

doi:10.6039/j.issn.1001-0408.2023.08.20

您当前的位置：

首页 >

文章列表页 >

Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children

更新时间：2023-04-25

- Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children
- ZHONGGUO YAOFANG Vol. 34, Issue 8, Pages: 1000-1004(2023)
- 作者机构：
  
  1.四川大学华西第二医院药学部/循证药学中心/国家药品监督管理局药物制剂体内外相关性技术研究重点实验室，成都　610041
  2.出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041
  3.四川大学华西药学院，成都　610041
  4.四川大学华西第二医院儿科，成都　610041
  5.四川大学转化医学中心分子转化医学实验室，成都　610041
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.08.20
  CLC： R952
- Published：30 April 2023，
  
  Received：17 August 2022，
  
  Revised：15 March 2023，
扫描看全文
黄亮,王其琼,陈力等.儿童罕见病多学科诊疗的药学服务模式探索 ^Δ[J].中国药房,2023,34(08):1000-1004.

HUANG Liang,WANG Qiqiong,CHEN Li,et al.Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children[J].ZHONGGUO YAOFANG,2023,34(08):1000-1004.
黄亮,王其琼,陈力等.儿童罕见病多学科诊疗的药学服务模式探索 ^Δ[J].中国药房,2023,34(08):1000-1004. DOI： 10.6039/j.issn.1001-0408.2023.08.20.

HUANG Liang,WANG Qiqiong,CHEN Li,et al.Exploration of pharmaceutical service model in multidisciplinary diagnosis and treatment of rare diseases in children[J].ZHONGGUO YAOFANG,2023,34(08):1000-1004. DOI： 10.6039/j.issn.1001-0408.2023.08.20.

摘要

目的

探索儿童罕见病多学科诊疗（MDT）的药学服务模式。

方法

四川大学华西第二医院（以下简称“我院”）临床药师参与儿童罕见病MDT过程，通过基于循证实践制定药物治疗方案，提高治疗药物可及性，药学监护，药物治疗管理，全程参与患儿诊疗过程，构建儿童罕见病MDT的药学服务模式。

结果

2021年1月－2022年4月，我院临床药师共累计参与39例罕见病患儿的MDT，包括罕见病住院患儿21例，罕见病门诊患儿18例，共涉及23种罕见病；完成罕见病住院患儿药学查房45例次、药学会诊26例次，罕见病门诊患儿MDT讨论25例次、药学门诊5例次，院内外罕见病患儿用药教育38例次，院外患儿随访25例次。有24例（61.54%）患儿涉及超说明书用药，涉及13种罕见病和16种治疗药品，其中11种药品已完成或正在进行超说明书用药备案；3种药品完成临时采购药品审核评估；完成医保药品和高值药品处方审核268例次。

结论

我院初步建立了儿童罕见病MDT“院内+院外、线上+线下”的闭环药学服务模式，该模式提高了我院儿童罕见病治疗药物的院内可及性、临床应用的规范性及儿童罕见病的诊疗水平。

Abstract

OBJECTIVE

To explore the pharmaceutical service model in multidisciplinary diagnosis and treatment （MDT） of rare diseases in children.

METHODS

Clinical pharmacists of West China Second University Hospital （hereinafter referred to as “our hospital”） participated in the process of MDT of children’s rare diseases. Clinical pharmacists took part in the entire diagnosis and treatment process of children and established the MDT pharmaceutical service model of children’s rare diseases by formulating drug treatment plans based on evidence-based practice， improving the accessibility of drugs， pharmaceutical monitoring and drug treatment management.

RESULTS

From January 2021 to April 2022， clinical pharmacists of our hospital had participated in a total of 39 cases of rare diseases MDT in children， including 21 hospitalized children with rare diseases and 18 outpatient children with rare diseases， involving a total of 23 rare diseases. Clinical pharmacists completed 45 pharmaceutical rounds and 26 pharmaceutical consultations for rare diseases inpatients， 25 outpatients’ MDT and 5 pharmaceutical outpatient service for outpatients with rare diseases， 38 medication educations for inpatients and outpatients with rare diseases and 25 follow-up services for out-of-hospital patients. There were 24 cases （61.54%） of off-label drug use， involving 13 rare diseases and 16 therapeutic drugs， among which off-label drug use registration of 11 drugs had been completed or was in progress. The temporary purchase evaluations of 3 drugs had been completed； 268 cases of medical insurance drug and high-value drug prescription had been reviewed.

CONCLUSIONS

Our hospital have primarily established a loop pharmaceutical service model of MDT for children with rare diseases， which covers inpatients and outpatients. The model improves the availability and standardization of clinical application of therapeutic drugs， and diagnosis and treatment level for children with rare diseases in our hospital.

关键词

儿童罕见病多学科诊疗临床药师药学服务

Keywords

rare diseasesmultidisciplinary team diagnosis and treatmentclinical pharmacistspharmaceutical service

references

张抒扬，赵玉沛. 罕见病学[M]. 北京：人民卫生出版社，2020：1-2.

丁若溪，张蕾，赵艺皓，等. 罕见病流行现状：一个极弱势人口的健康危机[J]. 人口与发展，2018，24（1）：72-84.

EPPS C，BAX R，CROKER A，et al. Global regulatory and public health initiatives to advance pediatric drug development for rare diseases[J]. Ther Innov Regul Sci，2022，56（6）：964-975.

潘锋，张浩臣. 提升罕见病诊疗与保障水平需建立多方协调机制[J]. 中国医药导报，2021，18（31）：1-3.

郝婵娟，倪鑫. 儿童罕见病诊治现状及展望[J]. 罕见病研究，2022，1（3）：229-232.

顾英，王卓英，汤小丽. 儿科用药现状分析与管理对策[J]. 中医药管理杂志，2022，30（1）：184-185.

陈运彬，颜慧恒. 儿童疾病规范化诊治和合理用药的管理思考[J]. 广东医学，2022，43（1）：1-4.

张抒扬，张学. 近年中国罕见病相关政策和实践探索[J]. 罕见病研究，2022，1（1）：1-6.

宋红梅，马明圣. MDT在儿童疑难罕见病诊疗中的应用与思考[J]. 中华医学信息导报，2020，35（22）：9.

龚力，何谦，李景宇，等. 罕见病新型管理模式探索与实践的华西经验[J]. 华西医学，2021，36（12）：1726-1729.

李景宇，陈一龙，龚力，等. 中国罕见病诊后医疗服务困境和智慧医疗助力对策分析[J]. 华西医学，2022，37（1）：92-96.

刘鑫，唐彦，张波，等. 超说明书用药在罕见病治疗领域的应用现状[J]. 国际药学研究杂志，2019，46（9）：685-690.

黄亮，张伶俐，曾力楠，等. 我院超说明书用药管理体系构建的实践与探索[J]. 中国药房，2019，30（1）：1-5.

国家卫生健康委办公厅.国家卫生健康委办公厅关于印发医疗机构药学门诊服务规范等5项规范的通知（国卫办医函〔2021〕520号）[EB/OL].（2021-10-09）[2022-06-20].http：//www.nhc.gov.cn/yzygj/s7659/202110/f76fc77-acd87458f950c86d7bc468f22.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/202110/f76fc77-acd87458f950c86d7bc468f22.shtml.

林茂，陈哲，曾力楠，等. 国内、外药物治疗管理文献研究现状分析[J]. 中国药房，2019，30（17）：2305-2310.

张抒扬. 北京协和医院罕见病多学科合作诊疗病例集：2021年版[M]. 北京：人民卫生出版社，2021：1-368.

谈仪炯，陈蓉，李琴，等. 临床药师对1例肾小管酸中毒合并低磷性骨软化症患者的药学监护[J]. 中南药学，2018，16（4）：559-562.

张喆，王璇，邹朗，等. 临床药师参与1例阵发性睡眠性血红蛋白尿伴血栓患者抗凝治疗药学实践[J]. 中国药业，2020，29（20）：43-46.

王琳，黄亮，孙小妹，等. 婴幼儿原发性甲状旁腺功能亢进所致高钙血症的循证治疗研究[J]. 中国药房，2018，29（23）：3255-3259.

杨佳，江永贤，陈文文，等. 先天性高胰岛素血症患儿的药学监护及自备药品安全管理模式的建立[J]. 药物不良反应杂志，2021，23（4）：202-204.

李淑娟，胡志灏，刘惠，等. 多学科团队合作对肝豆状核变性治疗模式探讨[J]. 中国病案，2018，19（8）：102-104.

甘贝贝. 罕见病药物特购“破冰”[N]. 健康报，2019-02-28（5）.

博鳌乐城国际医疗旅游先行区.国内首次！6位尿素循环障碍患儿成功在乐城接受罕见病创新药物RAVICTI®临床治疗[EB/OL].（2022-02-08）[2022-08-09]. http：//www.lecityhn.com/#/list_4a02d45c493f4b988-2a413abe3112df5/article?categoryId=4a02d45c493f4b98-82a413abe3112df5&articleId=3ee7b595f422418aa0504b-e2d9363a82http://www.lecityhn.com/#/list_4a02d45c493f4b988-2a413abe3112df5/article?categoryId=4a02d45c493f4b98-82a413abe3112df5&articleId=3ee7b595f422418aa0504b-e2d9363a82.

丁瑞琳，邵蓉. 超说明书用药的法律风险分析及政策完善建议[J]. 上海医药，2022，43（增刊2）：99-105.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on pharmaceutical care model for drug-related problems in elderly patients based on comprehensive medication management review

A qualitative study on the influencing factors of prescription circulation and its platform construction

Pharmacy construction and management of Yanqing Winter （Paralympic） Olympic Village Polyclinic for 2022 Beijing Winter （Paralympic） Olympic Games based on 4M1E method

Survey analysis of influential factors of medication compliance and adverse drug reactions of home-based patients with severe mental disorders in Jinshan district of Shanghai

Related Author

GONG Hui

LI Chen

SHAN Qing

LIU Wei

CHEN Hong

ZHAO Chuan

ZOU Hui

HUANG Zhuanqing

Related Institution

Dept. of Ophthalmology， the 944th Hospital of PLA

Outpatient Department， Jingzhong Medical District of PLA General Hospital

Cadre Diagnosis and Treatment Department， the Sixth Medical Center of PLA General Hospital

Translational Medicine Center， Department of Medical Innovation and Research， PLA General Hospital

Graduate School of PLA General Hospital

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰